NCT01180348.

Methods	Randomised, non‐inferiority trial, split‐face,active‐controlled, facial wrinkles, phase III trial
Participants	192 randomised female participants, age ranging from 18 years old to 65 years old Inclusion Criteria Patients who agree with all study procedures and sign for their own free will the TCLE Adult patients were female between 18 and 65 years, regardless of social condition Between skin phototype I and IV With good mental and physical health Patients who have not been treated with botulinum toxin type A Patients who agree to abstain from physical activity for a period of 24 hours, previous and subsequent to the initiation of the study Patients presenting at screening visit, wrinkles in the glabellar region between classes 2 and 3 of Table Wrinkles Pattern Classification, which is diagnosed Clinically by the dermatologist Exclusion Criteria Patients who are in classes 0 and 1 of the Table Pattern Classification Wrinkle Patients who have disorders or diseases that might interfere with neuromuscular function (myasthenia gravis or Lambert‐Eaton syndrome) Patients being treated with antibiotics (aminoglycosides) and muscle relaxants Patients with pre‐existing conditions such as ptosis or scars in the area to be assessed, as they may endanger the health of the patient and the results of the study Patients who have made treatments fill in the glabellar region (retinoic acid, collagen) Patients who have been treated in the dermatological peeling in the last three months Patients are using treatments cosmetics agents anti age (vitamin C pure retinoids flavonoids acid hyaluronic others) or used past 3 months Patients with known hypersensitivity to any component of the study drug Pregnant or lactating women Country: Brazil
Interventions	Intervention:3 applications on each side of the face in 15 predetermined sites in three regions of the face (front, glabellar, periocular). Botulift® 90 U Comparator: 3 applications on each side of the face in 15 predetermined sites in three regions of the face (front, glabellar, periocular).OnabotulinumtoxinA
Outcomes	Primary Outcomes Overall improved assessment of hyperkinetic facial lines in a state of relaxation and maximal contraction through the Honeck's scale and photographic images obtained by equipment Visia Digital Compexton Analysis (Canfield Imaging Systems, version 4.0.2) 30 days of application The non‐inferiority of T group compared to the group Co was demonstrated in evaluations in a state of relaxation and maximal contraction in the PP analysis population, because as defined for the study, the lower limits of 95% of the mean of these assessments (‐2.7% and ‐5.4%) are contained within the non‐inferiority limit set at ‐10% Secondary Outcomes Length of stay of the effect of botulinum toxin A (Test and Comparator) the 24‐week period.The action of both treatments decreases over time and there is no significant difference between the two treatments Safety of both botulinum toxin A. The occurrence of adverse events was similar in both groups
Notes	Sponsor Azidus Brasil We sent an email to this company (http://laboratoriobergamo.com.br/contato/) on June, 23rd, 2018. No answer.